1. Home
  2. GRI vs KTTA Comparison

GRI vs KTTA Comparison

Compare GRI & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRI
  • KTTA
  • Stock Information
  • Founded
  • GRI 2018
  • KTTA 2020
  • Country
  • GRI United States
  • KTTA United States
  • Employees
  • GRI N/A
  • KTTA N/A
  • Industry
  • GRI Biotechnology: Pharmaceutical Preparations
  • KTTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRI Health Care
  • KTTA Health Care
  • Exchange
  • GRI Nasdaq
  • KTTA Nasdaq
  • Market Cap
  • GRI 3.2M
  • KTTA 2.8M
  • IPO Year
  • GRI N/A
  • KTTA 2021
  • Fundamental
  • Price
  • GRI $1.38
  • KTTA $0.89
  • Analyst Decision
  • GRI Strong Buy
  • KTTA
  • Analyst Count
  • GRI 2
  • KTTA 0
  • Target Price
  • GRI $22.00
  • KTTA N/A
  • AVG Volume (30 Days)
  • GRI 358.1K
  • KTTA 2.3M
  • Earning Date
  • GRI 05-15-2025
  • KTTA 05-15-2025
  • Dividend Yield
  • GRI N/A
  • KTTA N/A
  • EPS Growth
  • GRI N/A
  • KTTA N/A
  • EPS
  • GRI N/A
  • KTTA N/A
  • Revenue
  • GRI N/A
  • KTTA N/A
  • Revenue This Year
  • GRI N/A
  • KTTA N/A
  • Revenue Next Year
  • GRI N/A
  • KTTA N/A
  • P/E Ratio
  • GRI N/A
  • KTTA N/A
  • Revenue Growth
  • GRI N/A
  • KTTA N/A
  • 52 Week Low
  • GRI $1.10
  • KTTA $0.79
  • 52 Week High
  • GRI $66.30
  • KTTA $7.50
  • Technical
  • Relative Strength Index (RSI)
  • GRI 39.90
  • KTTA 38.94
  • Support Level
  • GRI $1.24
  • KTTA $0.87
  • Resistance Level
  • GRI $1.49
  • KTTA $0.95
  • Average True Range (ATR)
  • GRI 0.12
  • KTTA 0.07
  • MACD
  • GRI 0.07
  • KTTA 0.01
  • Stochastic Oscillator
  • GRI 59.52
  • KTTA 40.41

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Share on Social Networks: